Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN 2: Telavancin vs Vancomycin for Hospital-Acquired Pneumonia
NCT00124020Phase 3Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jan 2005
- Primary completion
- May 2007
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telavancin in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Cumberland Pharmaceuticals. Primary endpoint: Clinical Response. Started Jan 2005; status: completed.
02
Drugs
telavancin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00124020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124020.